Tetherex Pharmaceuticals is developing novel products to treat thrombosis inflamatory disease and cancer. Its lead clinical program is focused on an antibody names SelK2 initally under development for the treat of venous thromboembolism and Crohn’s desease.
Year Founded: 2014
Year Partnered: 2014
Fund: Angel Fund II, Accelerate, Oklahoma Seed Capital Fund